Bharat Biotech's intranasal Covid vaccine iNCoVACC gets CDSCO Panel nod for PMS study
New Delhi: In a significant development, the vaccine manufacturer Bharat Biotech International Limited has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) for conducting an active post-marketing surveillance study (PMS study) of ChAd36-SARS-CoV-S COVID-19 Vaccine (recombinant) which is intranasal Covid-19 vaccine, iNCOVACC.
This came in line with the proposal presented by the vaccine major Bharat Biotech for conducting an active post-marketing surveillance study of ChAd36-SARS-CoV-S COVID-19 Vaccine (recombinant) as per the condition of manufacturing and marketing permission.
Intranasal Covid-19 vaccine, iNCOVACC is an Adenoviral vector-based (expressing a stabilized spike protein) SARSCoV-2 vaccine for nasal administration only. iNCOVACC vaccination course consists of TWO separate doses of 0.5mL ( 8 drops, 4 drops in each nostril). The second dose should be administered after 28 days ( 4 weeks from the first dose).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.